TCRT
Alaunos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.13
+19.01%Oct 13, 2026, 17:20 UTC
Alaunos Therapeutics, Inc. shares rose about 200% on Tuesday, with trading volume of 191.48 million shares versus an average of 826,167.
Source:Oct 13, 2026, 14:31 UTC
Alaunos Therapeutics, Inc. announced an oversubscribed $350 million private placement concurrent with its acquisition of Alaunos Therapeutics, Inc..
Source:Oct 13, 2026, 14:31 UTC
Alaunos Therapeutics, Inc. announced its acquisition of Alaunos Therapeutics, Inc..
Source:Oct 13, 2026, 13:32 UTC
Alaunos Therapeutics reported the departures of directors Robert W. Postma, Michael A. Jerman and Jaime W. Vieser.
Oct 13, 2026, 13:32 UTC
Alaunos Therapeutics appointed Peter Harwin as a director and member of its Nominating and Corporate Governance Committee, effective October 13, 2026.
Oct 9, 2026, 20:34 UTC
NASDAQ, INC. notified Alaunos Therapeutics that it violated NASDAQ, INC. Rule 5550(b)(1) for equity, and the company plans to request a hearing before the NASDAQ, INC. Hearings Panel.
Sep 22, 2026, 20:32 UTC
Alaunos Therapeutics, Inc. sold 380,469 shares of common stock at $1.46 per share and 386,654 pre-funded warrants at $1.459 per warrant in a registered direct offering, raising total gross proceeds of $1,120,000.54.
Sep 18, 2026, 08:25 UTC
Alaunos Therapeutics Inc approved and adopted its Second Amended and Restated By-Laws, effective immediately, according to a Securities and Exchange Commission filing.
Source: